User login
Key clinical point: Patients with KRAS p.G12C-mutant metastatic colorectal cancer (mCRC) show poor treatment outcomes, which are numerically worse than those in patients without this mutation or with KRAS non-p.G12C mutations, thus highlighting the prognostic value of KRAS p.G12C mutations.
Major finding: After the first-line therapy, the KRAS p.G12C, KRAS non-p.G12C, and non-KRAS (RAS/BRAF wild-type) mutation cohorts and the overall mCRC cohort had a median overall survival (95% CI) of 16.1 (13.0-19.0), 18.3 (17.2-19.3), 23.4 (21.9-24.9), and 19.2 (18.5-19.8) months and a median real-world progression-free survival (95% CI) of 7.4 (6.3-9.5), 9.0 (8.2-9.7), 10.6 (9.8-11.6), and 9.2 (8.6-9.7) months, respectively.
Study details: This retrospective real-world study included 6477 adult patients with mCRC and genomic sequencing data, of which 238, 2947, and 2249 had KRAS p.G12C, KRAS non-p.G12C, and non-KRAS mutations, respectively.
Disclosures: The study was funded by Amgen Inc. Some authors reported serving as consultants or advisors for and receiving honoraria or research funds from various sources, including Amgen. The other authors are employees of Amgen.
Source: Fakih M et al. Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer. Oncologist. 2022 (Apr 26). Doi: 10.1093/oncolo/oyac077
Key clinical point: Patients with KRAS p.G12C-mutant metastatic colorectal cancer (mCRC) show poor treatment outcomes, which are numerically worse than those in patients without this mutation or with KRAS non-p.G12C mutations, thus highlighting the prognostic value of KRAS p.G12C mutations.
Major finding: After the first-line therapy, the KRAS p.G12C, KRAS non-p.G12C, and non-KRAS (RAS/BRAF wild-type) mutation cohorts and the overall mCRC cohort had a median overall survival (95% CI) of 16.1 (13.0-19.0), 18.3 (17.2-19.3), 23.4 (21.9-24.9), and 19.2 (18.5-19.8) months and a median real-world progression-free survival (95% CI) of 7.4 (6.3-9.5), 9.0 (8.2-9.7), 10.6 (9.8-11.6), and 9.2 (8.6-9.7) months, respectively.
Study details: This retrospective real-world study included 6477 adult patients with mCRC and genomic sequencing data, of which 238, 2947, and 2249 had KRAS p.G12C, KRAS non-p.G12C, and non-KRAS mutations, respectively.
Disclosures: The study was funded by Amgen Inc. Some authors reported serving as consultants or advisors for and receiving honoraria or research funds from various sources, including Amgen. The other authors are employees of Amgen.
Source: Fakih M et al. Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer. Oncologist. 2022 (Apr 26). Doi: 10.1093/oncolo/oyac077
Key clinical point: Patients with KRAS p.G12C-mutant metastatic colorectal cancer (mCRC) show poor treatment outcomes, which are numerically worse than those in patients without this mutation or with KRAS non-p.G12C mutations, thus highlighting the prognostic value of KRAS p.G12C mutations.
Major finding: After the first-line therapy, the KRAS p.G12C, KRAS non-p.G12C, and non-KRAS (RAS/BRAF wild-type) mutation cohorts and the overall mCRC cohort had a median overall survival (95% CI) of 16.1 (13.0-19.0), 18.3 (17.2-19.3), 23.4 (21.9-24.9), and 19.2 (18.5-19.8) months and a median real-world progression-free survival (95% CI) of 7.4 (6.3-9.5), 9.0 (8.2-9.7), 10.6 (9.8-11.6), and 9.2 (8.6-9.7) months, respectively.
Study details: This retrospective real-world study included 6477 adult patients with mCRC and genomic sequencing data, of which 238, 2947, and 2249 had KRAS p.G12C, KRAS non-p.G12C, and non-KRAS mutations, respectively.
Disclosures: The study was funded by Amgen Inc. Some authors reported serving as consultants or advisors for and receiving honoraria or research funds from various sources, including Amgen. The other authors are employees of Amgen.
Source: Fakih M et al. Real-world study of characteristics and treatment outcomes among patients with KRAS p.G12C-mutated or other KRAS mutated metastatic colorectal cancer. Oncologist. 2022 (Apr 26). Doi: 10.1093/oncolo/oyac077